RIG2 Stock Chart & Stats
€25.06
€0.74(2.90%)
At close: 4:00 PM EST
€25.06
€0.74(2.90%)
Day’s Range― - ―
52-Week Range€24.60 - €36.66
Previous CloseN/A
Volume200.00
Average Volume (3M)340.00
Market Cap
€5.89B
Enterprise Value€1.86M
Total Cash (Recent Filing)€136.62B
Total Debt (Recent Filing)€21.74B
Price to Earnings (P/E)9.3
Beta0.51
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1306.92
Shares Outstanding186,374,860
10 Day Avg. Volume947
30 Day Avg. Volume340
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.59Price Target Upside61.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chemical Works of Gedeon Richter News
RIG2 FAQ
What was Chemical Works of Gedeon Richter Plc’s price range in the past 12 months?
Chemical Works of Gedeon Richter Plc lowest stock price was €24.60 and its highest was €36.66 in the past 12 months.
What is Chemical Works of Gedeon Richter Plc’s market cap?
Chemical Works of Gedeon Richter Plc’s market cap is €5.89B.
When is Chemical Works of Gedeon Richter Plc’s upcoming earnings report date?
Chemical Works of Gedeon Richter Plc’s upcoming earnings report date is Aug 07, 2026 which is in 12 days.
How were Chemical Works of Gedeon Richter Plc’s earnings last quarter?
Chemical Works of Gedeon Richter Plc released its earnings results on May 12, 2026. The company reported €0.981 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Chemical Works of Gedeon Richter Plc overvalued?
According to Wall Street analysts Chemical Works of Gedeon Richter Plc’s price is currently Undervalued.
Does Chemical Works of Gedeon Richter Plc pay dividends?
Chemical Works of Gedeon Richter Plc does not currently pay dividends.
What is Chemical Works of Gedeon Richter Plc’s EPS estimate?
Chemical Works of Gedeon Richter Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chemical Works of Gedeon Richter Plc have?
Chemical Works of Gedeon Richter Plc has 186,374,860 shares outstanding.
What happened to Chemical Works of Gedeon Richter Plc’s price movement after its last earnings report?
Chemical Works of Gedeon Richter Plc reported an EPS of €0.981 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.668%.
Which hedge fund is a major shareholder of Chemical Works of Gedeon Richter Plc?
Currently, no hedge funds are holding shares in DE:RIG2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemical Works of Gedeon Richter Plc
Chemical Works of Gedeon Richter Plc engages in the development and manufacture of pharmaceuticals. It operates through the following segments: Pharmaceuticals, Wholesale & Retail, and Others. The Pharmaceutical segment engages in research and development, manufacturing, sales and marketing of pharmaceutical products. The Wholesale & Retail segment represents the distribution of companies and pharmacies that are part of the sales network in various regional markets and, as such, convey its products to consumers. The Other segment relates to the business of the members of the group that provide marketing and sales support services. The company was founded by Gedeon Richter in 1901 and is headquartered in Budapest, Hungary.
RIG2 Stock 12 Month Forecast
Average Price Target
€40.59
▲(61.96% Upside)
Technical Analysis
Chemical Works of Gedeon Richter
―
Dr Reddy's Laboratories
―
Teva Pharmaceutical
―
Perrigo Company
―
AstraZeneca
―
Pfizer
―
GlaxoSmithKline
―








